Cilostazol

• CAT Number: A000281
• CAS Number: 73963-72-1
• Molecular Formula: C₂₀H₂₇N₅O₂
• Molecular Weight: 369.46
• Purity: ≥95%
• Target: PDE
• Solubility: >15.4mg/mL in DMSO
• Storage: -20°C
• InChI: InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
• InChIKey: RRGUKTPIGVIEKM-UHFFFAOYSA-N
• SMILES: C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4

Cilostazol is a quinolinone-derivative medication used in the alleviation of the symptom of claudication in individuals with peripheral vascular disease. Cilostazol is a phosphodiesterase inhibitor with therapeutic focus on cyclic adenosine monophosphate (cAMP). It inhibits platelet aggregation and is a direct arterial vasodilator. Its main effects are dilation of the arteries supplying blood to the legs and decreasing platelet coagulation. It is under the trade name Pletal.

Reference

1: Oguchi T, Ono R, Tsuji M, Shozawa H, Somei M, Inagaki M, Mori Y, Yasumoto T,
Ono K, Kiuchi Y. Cilostazol Suppresses Aβ-induced Neurotoxicity in SH-SY5Y Cells
through Inhibition of Oxidative Stress and MAPK Signaling Pathway. Front Aging
Neurosci. 2017 Oct 17;9:337. doi: 10.3389/fnagi.2017.00337. eCollection 2017.
PubMed PMID: 29089887; PubMed Central PMCID: PMC5651005.

2: Ohtomo R, Bannai T, Ohtomo G, Shindo A, Tomimoto H, Tsuji S, Iwata A.
Cilostazol alleviates white matter degeneration caused by chronic cerebral
hypoperfusion in mice: Implication of its mechanism from gene expression
analysis. Neurosci Lett. 2017 Oct 27;662:247-252. doi:
10.1016/j.neulet.2017.10.045. [Epub ahead of print] PubMed PMID: 29080698.

3: Saito S, Kojima S, Oishi N, Kakuta R, Maki T, Yasuno F, Nagatsuka K, Yamamoto
H, Fukuyama H, Fukushima M, Ihara M. A multicenter, randomized,
placebo-controlled trial for cilostazol in patients with mild cognitive
impairment: The COMCID study protocol. Alzheimers Dement (N Y). 2016 Oct
27;2(4):250-257. doi: 10.1016/j.trci.2016.10.001. eCollection 2016 Nov. PubMed
PMID: 29067312; PubMed Central PMCID: PMC5651350.

4: Shenthar J, Chakali SS, Acharya D, Parvez J, Banavalikar B. Oral quinine
sulfate for the treatment of electrical storm and prevention of recurrent shocks
in Brugada syndrome after failed cilostazol therapy. HeartRhythm Case Rep. 2017
Aug 24;3(10):470-474. doi: 10.1016/j.hrcr.2017.07.005. eCollection 2017 Oct.
PubMed PMID: 29062700; PubMed Central PMCID: PMC5643860.

5: Oelze M, Welschof P, Knorr M, Tran LP, Ullmann E, Stamm P, Kröller-Schön S,
Jansen T, Kopp M, Schulz E, Gori T, Burgin K, Scherhag A, Sartor D, Münzel T,
Daiber A. Basic in vitro Characterization of the Vasodilatory Potential of
2-Aminoethyl Nitrate Fixed-Dose Combinations with Cilostazol, Metoprolol and
Valsartan. Pharmacology. 2017 Oct 7;101(1-2):54-63. doi: 10.1159/000480434. [Epub
ahead of print] PubMed PMID: 28988245.

6: Nurullahoğlu-Atalık KE, Kutlu S, Solak H, Koca RÖ. Cilostazol enhances
atorvastatin-induced vasodilation of female rat aorta during aging. Physiol Int.
2017 Sep 1;104(3):226-234. doi: 10.1556/2060.104.2017.3.3. PubMed PMID: 28956637.

7: Galyfos G, Sianou A. Cilostazol for Secondary Prevention of Stroke: Should the
Guidelines Perhaps Be Extended? Vasc Specialist Int. 2017 Sep;33(3):89-92. doi:
10.5758/vsi.2017.33.3.89. Epub 2017 Sep 30. Review. PubMed PMID: 28955697; PubMed
Central PMCID: PMC5614376.

8: Holland PR, Strother L. Cilostazol as a chemically induced preclinical model
of migraine. Cephalalgia. 2017 Jan 1:333102417693832. doi:
10.1177/0333102417693832. [Epub ahead of print] PubMed PMID: 28952338.

9: Christensen SL, Petersen S, Sørensen DB, Olesen J, Jansen-Olesen I. Cilostazol
induces C-fos expression in the trigeminal nucleus caudalis and behavioural
changes suggestive of headache with the migraine-like feature photophobia in
female rats. Cephalalgia. 2017 Jan 1:333102417693833. doi:
10.1177/0333102417693833. [Epub ahead of print] PubMed PMID: 28952321.

10: Xiong XR, Lan DL, Li J, Lin YQ, Li MY. Supplementation of cilostazol during
in vitro maturation enhances the meiosis and developmental competence of yak
oocytes by influencing cAMP content and mRNA expression. Anim Reprod Sci. 2017
Nov;186:21-30. doi: 10.1016/j.anireprosci.2017.08.013. Epub 2017 Aug 24. PubMed
PMID: 28935242.